Table 1.

Sequences of linear peptides on α3(IV)NC1 and frequencies and levels of antibodies against them in sera from patients with anti-glomerular basement membrane disease

Peptide	Sequence from N-Terminal	Position from N-Terminal	Recognition, n (%)	Mean Levels of Antibodies
P1	SPATWTTRGFVFTRHSQTTA	1–20	0	—
P2	VFTRHSQTTAIPSCPEGTVPL	11–31	1 (1.5)	0.10
P3	TAIPSCPEGTVPLYSGFSFLFV	19–40	6 (8.8)	0.51
P4	LYSGFSFLFVQGNQRAHGQD	31–50	6 (8.8)	0.18
P5	QGNQRAHGQDLGTLGSCLQR	41–60	0	—
P6	LGTLGSCLQRFTTMPFLFCN	51–70	4 (5.9)	0.30
P7	FTTMPFLFCNVNDVCNFASR	61–80	4 (5.9)	0.30
P8	VNDVCNFASRNDYSYWLSTPA	71–91	4 (5.9)	0.18
P9	NDYSYWLSIPALMPMNMAPI	81–100	4 (5.9)	0.92
P10	ALMPMNMAPITGRALEPYIS	91–110	2 (2.9)	0.44
P11	TGRALEPYISRCTVCEGPAI	101–120	1 (1.5)	0.79
P12	RCTVCEGPAIAIAVHSQTTD	111–130	0	—
P13	AIAVHSQTTDIPPCPHGWIS	121–140	4 (5.9)	0.35
P14	TDIPPCPHGWISLWKGFSFIMF	129–150	28 (41.2)	0.29
	LWKGFSFIMFTSAGSEGTGQa	141–160
P15	TSAGSEGTGQALASPGSCLE	151–170	7 (10.3)	0.79
P16	ALASPGSCLEEFRASPFLEC	161–180	25 (36.8)	0.72
P17	EFRASPFLECHGRGTCNYYS	171–190	5 (7.4)	0.50
P18	HGRGTCNYYSNSYSFWLASL	181–200	39 (57.4)	1.29
P19	NSYSFWLASLNPERMFRKPI	191–210	4 (5.9)	0.09
P20	NPERMFRKPIPSTVKAGELE	201–220	3 (4.4)	0.27
P21	PSTVKAGELEKIISRCQVCM	211–230	7 (10.3)	0.46
P22	KIISRCQVCMKKRH	221–234	15 (22.1)	0.38
P23	KGFSFIMFTSAGSEb	143–156	—	—
P24	FIMFTSAGSEGTGQ	157–160	2 ( 2.9)	0.18

N=68 patients.

^aThis sequence was not available for peptide synthesis due to synthetic difficulties. Two smaller peptides derived from it were then designed and successfully synthesized as P23 and P24.

^bP23 was insoluble and could not be tested in ELISA.